Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 139603, Ly
2. Atomoxetine
3. Atomoxetine Hcl
4. Hcl, Atomoxetine
5. Hydrochloride, Atomoxetine
6. Ly 139603
7. N-methyl-gamma-(2-methylphenoxy)benzenepropanamine Hydrochloride
8. Strattera
9. Tomoxetine
10. Tomoxetine Hydrochloride, (+)-isomer - T351671
11. Tomoxetine Hydrochloride, (+-)-isomer
12. Tomoxetine Hydrochloride, (-)-isomer
1. Atomoxetine Hcl
2. 82248-59-7
3. Tomoxetine Hydrochloride
4. Strattera
5. (r)-tomoxetine Hydrochloride
6. (r)-n-methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine Hydrochloride
7. Atomoxetine, Hcl
8. Atomoxetine Hydrochloride [usan]
9. (r)-(-)-tomoxetine Hydrochloride
10. Ly 139603
11. Atomoxetine (hydrochloride)
12. Ly-139603
13. Atomoxetine (as Hydrochloride)
14. 57wvb6i2w0
15. (-)-n-methyl-3-phenyl-3-(o-tolyloxy)propylamine Hydrochloride
16. Chebi:331697
17. (r)-atomoxetine Hydrochloride
18. Nsc-759104
19. Dsstox_cid_24266
20. Dsstox_rid_80136
21. Dsstox_gsid_44266
22. Smr000469177
23. Cas-82248-59-7
24. Unii-57wvb6i2w0
25. (3r)-n-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine;hydrochloride
26. Strattera (tn)
27. Mfcd06410992
28. Ncgc00016056-02
29. Chembl1702
30. Mls001401377
31. Mls002153176
32. Schembl122111
33. Atomoxetine Hcl [vandf]
34. Dtxsid2044266
35. Atomoxetine Hydrochloride- Bio-x
36. Atomoxetine Hydrochloride Solution
37. Ly 139603 Hcl
38. Hms3413c05
39. Hms3677c05
40. (r)-n-methyl-3-phenyl-3-(o-tolyloxy)propan-1-aminehydrochloride
41. (r)-tomoxetine Hydrochloride, Solid
42. Tox21_110292
43. Atomoxetine Hydrochloride (jan/usp)
44. Ly-139602 [(+)-isomer]
45. S3175
46. Atomoxetine Hydrochloride [mi]
47. (3r)-n-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine Hydrochloride
48. Akos015920150
49. Benzenepropanamine, N-methyl-gamma-(2-methylphenoxy)-, Hydrochloride, (-)-
50. Tox21_110292_1
51. Atomoxetine Hydrochloride [jan]
52. Ccg-100874
53. Cs-1085
54. Ks-1223
55. Nc00124
56. Nsc 759104
57. Atomoxetine For Impurity A Identification
58. Atomoxetine Hydrochloride [mart.]
59. Ncgc00025345-02
60. Atomoxetine Hydrochloride [usp-rs]
61. Atomoxetine Hydrochloride [who-dd]
62. Bm164222
63. Hy-17385
64. Ly-135252
65. Am20060733
66. Sw197504-3
67. Atomoxetine Hydrochloride [ep Monograph]
68. Atomoxetine Hydrochloride [orange Book]
69. D02574
70. Atomoxetine Hydrochloride [usp Monograph]
71. 248t597
72. Sr-01000597779
73. Sr-01000763397
74. Sr-01000597779-1
75. Sr-01000763397-3
76. Q27225729
77. F0001-2408
78. Atomoxetine Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
79. (r)-n-methyl-?-(2-methylphenoxy)-benzenepropanamine Hydrochloride
80. (r)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamine Hydrochloride
81. (r)-n-methyl-3-phenyl-3-(o-tolyloxy)-propan-1-amine Hydrochloride
82. (r)-n-methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine Hcl
83. (r)-(-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamine Hydrochloride
84. (r)-n-methyl-gamma-(2-methylphenoxy)-benzenepropanamine Hydrochloride
85. Atomoxetine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
86. Methyl-((r)-3-phenyl-3-o-tolyloxy-propyl)-amine Hydrochloride
87. Atomoxetine For Impurity A Identification, European Pharmacopoeia (ep) Reference Standard
88. Atomoxetine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
89. Atomoxetine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
90. Benzenepropanamine, N-methyl-.gamma.-(2-methylphenoxy)-, Hydrochloride, (-)
91. Atomoxetine Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 291.8 g/mol |
---|---|
Molecular Formula | C17H22ClNO |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 6 |
Exact Mass | 291.1389920 g/mol |
Monoisotopic Mass | 291.1389920 g/mol |
Topological Polar Surface Area | 21.3 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 237 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Atomoxetine hydrochloride |
Drug Label | STRATTERA (atomoxetineHCl) is a selective norepinephrine reuptake inhibitor. AtomoxetineHCl is the R(-) isomer as determined by xray diffraction. The chemical designation is (-)-N-Methyl-3-phenyl-3-(o-tolyloxy)-propylamine hydrochloride. The... |
Active Ingredient | Atomoxetine hydrochloride |
Dosage Form | Capsule |
Route | oral |
Strength | 18mg; 100mg; 25mg; 60mg; 10mg; 80mg; 40mg |
Market Status | Tentative Approval |
Company | Mylan Pharms; Glenmark Generics; Aurobindo Pharma Usa; Apotex; Dr Reddys Labs; Sandoz; Sun Pharma Global |
2 of 4 | |
---|---|
Drug Name | Strattera |
PubMed Health | Atomoxetine (By mouth) |
Drug Classes | Central Nervous System Agent |
Drug Label | STRATTERA (atomoxetineHCl) is a selective norepinephrine reuptake inhibitor. AtomoxetineHCl is the R(-) isomer as determined by x-ray diffraction. The chemical designation is (-)-N-Methyl-3-phenyl-3-(o-tolyloxy)-propylamine hydrochloride. The m... |
Active Ingredient | Atomoxetine hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | 18mg; 25mg; 100mg; 60mg; 10mg; 80mg; 40mg |
Market Status | Prescription |
Company | Lilly |
3 of 4 | |
---|---|
Drug Name | Atomoxetine hydrochloride |
Drug Label | STRATTERA (atomoxetineHCl) is a selective norepinephrine reuptake inhibitor. AtomoxetineHCl is the R(-) isomer as determined by xray diffraction. The chemical designation is (-)-N-Methyl-3-phenyl-3-(o-tolyloxy)-propylamine hydrochloride. The... |
Active Ingredient | Atomoxetine hydrochloride |
Dosage Form | Capsule |
Route | oral |
Strength | 18mg; 100mg; 25mg; 60mg; 10mg; 80mg; 40mg |
Market Status | Tentative Approval |
Company | Mylan Pharms; Glenmark Generics; Aurobindo Pharma Usa; Apotex; Dr Reddys Labs; Sandoz; Sun Pharma Global |
4 of 4 | |
---|---|
Drug Name | Strattera |
PubMed Health | Atomoxetine (By mouth) |
Drug Classes | Central Nervous System Agent |
Drug Label | STRATTERA (atomoxetineHCl) is a selective norepinephrine reuptake inhibitor. AtomoxetineHCl is the R(-) isomer as determined by x-ray diffraction. The chemical designation is (-)-N-Methyl-3-phenyl-3-(o-tolyloxy)-propylamine hydrochloride. The m... |
Active Ingredient | Atomoxetine hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | 18mg; 25mg; 100mg; 60mg; 10mg; 80mg; 40mg |
Market Status | Prescription |
Company | Lilly |
Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Adrenergic Uptake Inhibitors
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
78
PharmaCompass offers a list of Atomoxetin Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Atomoxetin Hydrochloride manufacturer or Atomoxetin Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Atomoxetin Hydrochloride manufacturer or Atomoxetin Hydrochloride supplier.
PharmaCompass also assists you with knowing the Atomoxetin Hydrochloride API Price utilized in the formulation of products. Atomoxetin Hydrochloride API Price is not always fixed or binding as the Atomoxetin Hydrochloride Price is obtained through a variety of data sources. The Atomoxetin Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Atomoxetine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Atomoxetine, including repackagers and relabelers. The FDA regulates Atomoxetine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Atomoxetine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Atomoxetine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Atomoxetine supplier is an individual or a company that provides Atomoxetine active pharmaceutical ingredient (API) or Atomoxetine finished formulations upon request. The Atomoxetine suppliers may include Atomoxetine API manufacturers, exporters, distributors and traders.
click here to find a list of Atomoxetine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Atomoxetine DMF (Drug Master File) is a document detailing the whole manufacturing process of Atomoxetine active pharmaceutical ingredient (API) in detail. Different forms of Atomoxetine DMFs exist exist since differing nations have different regulations, such as Atomoxetine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Atomoxetine DMF submitted to regulatory agencies in the US is known as a USDMF. Atomoxetine USDMF includes data on Atomoxetine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Atomoxetine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Atomoxetine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Atomoxetine Drug Master File in Japan (Atomoxetine JDMF) empowers Atomoxetine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Atomoxetine JDMF during the approval evaluation for pharmaceutical products. At the time of Atomoxetine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Atomoxetine suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Atomoxetine Drug Master File in Korea (Atomoxetine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Atomoxetine. The MFDS reviews the Atomoxetine KDMF as part of the drug registration process and uses the information provided in the Atomoxetine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Atomoxetine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Atomoxetine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Atomoxetine suppliers with KDMF on PharmaCompass.
A Atomoxetine CEP of the European Pharmacopoeia monograph is often referred to as a Atomoxetine Certificate of Suitability (COS). The purpose of a Atomoxetine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Atomoxetine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Atomoxetine to their clients by showing that a Atomoxetine CEP has been issued for it. The manufacturer submits a Atomoxetine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Atomoxetine CEP holder for the record. Additionally, the data presented in the Atomoxetine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Atomoxetine DMF.
A Atomoxetine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Atomoxetine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Atomoxetine suppliers with CEP (COS) on PharmaCompass.
A Atomoxetine written confirmation (Atomoxetine WC) is an official document issued by a regulatory agency to a Atomoxetine manufacturer, verifying that the manufacturing facility of a Atomoxetine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Atomoxetine APIs or Atomoxetine finished pharmaceutical products to another nation, regulatory agencies frequently require a Atomoxetine WC (written confirmation) as part of the regulatory process.
click here to find a list of Atomoxetine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Atomoxetine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Atomoxetine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Atomoxetine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Atomoxetine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Atomoxetine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Atomoxetine suppliers with NDC on PharmaCompass.
Atomoxetine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Atomoxetine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Atomoxetine GMP manufacturer or Atomoxetine GMP API supplier for your needs.
A Atomoxetine CoA (Certificate of Analysis) is a formal document that attests to Atomoxetine's compliance with Atomoxetine specifications and serves as a tool for batch-level quality control.
Atomoxetine CoA mostly includes findings from lab analyses of a specific batch. For each Atomoxetine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Atomoxetine may be tested according to a variety of international standards, such as European Pharmacopoeia (Atomoxetine EP), Atomoxetine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Atomoxetine USP).